![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 17, 15028-15034, April 26, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the
Received for publication, January 16, 2002, and in revised form, February 6, 2002
Recent studies have initiated a paradigm shift in
the understanding of the function of heat shock proteins (HSP). It is
now clear that HSP can and do exit mammalian cells, interact with cells
of the immune system, and exert immunoregulatory effects. We recently
demonstrated that exogenously added HSP70 possesses potent cytokine
activity, with the ability to bind with high affinity to the plasma
membrane, elicit a rapid intracellular Ca2+ flux,
activate NF- Innate immunity is the first line of host defense against
infection and malignant transformation and has a profound effect on the
establishment of adaptive immunity (1, 2). Cells of the innate
immune system are adorned with recognition structures called pattern
recognition receptors (2, 3). Pattern recognition receptors such as
Toll-like receptors (TLRs),1
CD14, Heat shock proteins (HSP) are highly conserved proteins found in all
prokaryotes and eukaryotes. Under normal physiological conditions HSP
are expressed at low levels (12). However, a wide variety of stressful
stimuli including environmental (UV radiation, heat shock, heavy
metals, and amino acids), pathological (viral, bacterial, parasitic
infections or fever, inflammation, malignancy, or autoimmunity), or
physiological stimuli (growth factors, cell differentiation, hormonal
stimulation, or tissue development), induce a marked increase in
intracellular HSP synthesis (13), known as the stress response. The
primary function ascribed to HSP is as intracellular molecular
chaperones of naïve, aberrantly folded, or mutated proteins as
well as in cytoprotection following the kinds of stressful stimuli
mentioned above. Recent findings showing that both HSP60 (14) and HSP70
(15, 16) can use CD14 to induce the generation of proinflammatory
cytokines suggest that HSPs might represent a novel class of putative
endogenous ligands for TLRs
In this report, we address the signal transduction cascade stimulated
by exogenous HSP70 and reveal that HSP70-induced NF- Isolation and Enrichment of Human DCS--
Peripheral blood
mononuclear cells were isolated from freshly drawn peripheral venous
blood (Kraft Family Blood Center, Dana-Farber Cancer Institute) using
the Ficoll-Paque separation technique as described in detail elsewhere
(17). Monocytes were enriched from the peripheral blood mononuclear
cell fraction by negative depletion using magnetic beads coated with
appropriate monoclonal antibodies. Briefly, using a monocyte isolation
kit (Miltenyi Biotec, Aubum, CA), peripheral blood mononuclear cells
were treated with FcR blocking agent followed by hapten-antibody
mixture containing monoclonal hapten-conjugated CD3 (mouse Ig2A), CD7
(mouse Ig2A), CD19 (mouse IgG1), CD45RA (mouse IgG1), CD56 (mouse
IgG2b), and anti-IgE (mouse IgG2A) antibodies and incubated for 5 min
at 4 °C. Cells were washed twice in phosphate-buffered saline and
incubated in FcR blocking buffer and MACs anti-hapten microbeads. After a 5-min incubation at 4 °C, cells were washed and passed through a
column attached to a magnet. Unlabeled monocytes
(CD45+CD14+) eluted from the column were >98%
pure, as judged by flow cytometry. Cell viability was measured by
Trypan blue exclusion. CD45+CD14+ monocytes
were cultured for 8 days in RPMI (supplemented with 2 mM
glutamine, 100 units/ml penicillin/streptomycin, and 1% autologous serum). To generate DC, cells were treated with granulocyte
macrophage-colony stimulating factor (500 units/ml) and IL-4 (800 units/ml) on day 0. On day 4 of culture, granulocyte macrophage-colony
stimulating factor was added to the cells.
Cell Lines and Tissue Culture Conditions--
HEK293 cells
(ATCC, Rockville, MD) were maintained in Dulbecco's modified Eagle's
medium (ATCC) supplemented with 10% fetal bovine serum, 100 units/ml
penicillin G, 100 µg/ml streptomycin, and 2 mM
L-glutamine, and 2% sodium bicarbonate. Cells were
cultured at 37 °C in 5% CO2, 95% air humidified
incubator. At ~70-90% confluence, cells were harvested using
trypsin-EDTA, washed, and counted using a hemocytometer. Cells were
grown in this fashion for no more than 10 passages.
Construction of Human Dominant Negative (DN) TLR2 and
TLR4--
Mutations corresponding to the dominant negative TLR4 (P712H
substitution) in C3H/HeJ-mice were introduced into hemaggultinin-tagged cDNAs of human TLR2 and TLR4 (kindly provided by Felix Randow) by
PCR-directed mutagenesis, sequenced, and subcloned into the expression
plasmid pRc/CMV (Invitrogen).
Transient Transfection of Cells and Measurement of Luciferase
Activity--
Transient transfection of HEK293 (293 wild type),
293-TLR2, 293-TLR4, or 293-TLR2+4 cells was performed using FuGENE 6 (Roche Molecular Biochemicals) transfection reagent following the
manufacturer's instructions. Briefly, cells were incubated with
plasmids containing 1 µg of NF- Flow Cytometric Analysis--
Following treatment, 2 × 106 cells were simultaneously fixed and permeabilized using
2 ml of PermeaFix (OrthoDiagnostics, Raritan, NJ) for 40 min at room
temperature in the dark, as previously described. Cells were then
washed three times in phosphate-buffered saline. Nonspecific binding
was inhibited by treating cells with 5.5% normal goat serum in
phosphate-buffered saline for an additional 1 h at room
temperature with gentle rocking. For the measurement of co-stimulatory
molecule expression, cells were treated with anti-human CD86- Assay of Proliferation--
To determine the amount of
proliferation, following the various treatment protocols the cells were
pulsed with [3H]methylthymidine ([3H]TdR;
specific activity 2 Ci/mol; PerkinElmer Life Science, Beverly, MA) for
8 h. When incubated with rapidly proliferating cells, [3H]TdR incorporates into the DNA. The amount of cellular
incorporation of [3H]TdR is then estimated by liquid scintillography.
Exogenous HSP70 Activates NF- Mechanism by Which HSP70 Activates NF- Signaling Intermediates in HSP70-induced NF- Biological Significance of HSP70-induced NF-
To further demonstrate that CD14, TLR2, and TLR4 are required for
potent HSP70-induced cytokine production, we grew HEK293 cells on
culture slides. The cells were then transfected with CD14 alone or CD14 + TLR2 or CD14 + TLR2 + TLR4 followed by stimulation with equimolar
amounts (0.1 µg/ml) of HSP70 or control protein OVA for 4 h at
37 °C, stained with IL-6-fluorescein isothiocyanate, mounted with a
4,6-diamidino-2-phenylindole-based mounting media, and analyzed using
fluorescence microscope (Fig.
7A). In accordance with the
luciferase data, HEK293 cells transfected with CD14 + TLR2 and
stimulated with HSP70 but not control protein OVA, resulted in enhanced
intracellular IL-6 production (Fig. 7A). As expected, HEK293
cells transfected with CD14 + TLR2 + TLR4, when stimulated with HSP70
but not control protein OVA, resulted in potent augmentation of
intracellular IL-6 production, which was far in excess to that of HSP70
stimulated HEK293 cells transfected with CD14 + TLR2 (Fig.
7A) or CD14 + TLR4 (data not shown). Extracellular HSP70 was
not effective at stimulating intracellular IL-6 production from HEK293
cells transiently transfected with either TLR vector alone or CD14
alone (Fig. 7A). The phase-contrast images show the total
number of cells that were present at the time of the experiment (Fig.
7B).
This report for the first time demonstrates that HSP70-induced
proinflammatory cytokine production is mediated via the MyD88/NF- A major concern of these studies was to ascertain that our
HSP70-induced effects were not being masked by endotoxin contamination. We show that boiling (100 °C, 1 h) abrogated HSP70 but not
LPS-induced effects (Table I). In addition, pretreatment with LPS
antagonist, Polymyxin B abrogated LPS but not HSP70 effects (Fig. 2).
We also performed the Limulus lysate assay (BioWhittaker) on every
HSP70 sample and all reagents and culture media used in the experiments to ensure that LPS contamination was always below 5 pg/ml. Taken together, these results demonstrate that the effect of HSP70 are thus
genuine properties of HSP70 rather than due to endotoxin contamination.
The requirement for CD14 in HSP70-induced signaling via TLR is in line
with our previous findings that CD14 is a co-receptor for HSP70-induced
proinflammatory cytokine production in human monocytes (15). It has
been known that host recognition of microbial products like LPS,
peptidoglycan, and bacterial lipoprotein is principally mediated by
either a membrane-bound or by a soluble form of the glycoprotein, CD14
(for review, see Refs. 34 and 35). Ligation of microbial products to
CD14 triggers the production of proinflammatory cytokines. However,
CD14 is a gylcosylphosphatidylinositol-anchored membrane protein,
devoid of an intracellular domain (36). The mechanism by which CD14
transmits signals was until recently unknown. Studies of mammalian TLRs
have now provided intriguing evidence that TLRs are the CD14-associated
signal transducers for different classes of microbial products. Here we
show that CD14 is required for optimal HSP70-induced signaling via TLR2
and TLR4 (Fig. 4). This is unique since HSP60 (14) and LPS (34) have
recently been shown to utilize only TLR4 and CD14 for signaling that
results in the induction of proinflammatory cytokines (14).
Ozinsky and co-workers (37) have recently shown that both TLR2 and TLR6
are required for macrophage-mediated TNF- The biological significance and diversity of responses attributed to
HSP70 is remarkable. The term chaperokine has recently been coined to
better describe the ability of HSP70 to act as a chaperone and cytokine
(15, 18). In addition to functioning as an antigen carrier, HSP70
coupled to peptides has recently been shown to induce cytokine
production (42). Furthermore, a recombinant HIV p24-HSP70 fusion
protein elicits both humoral and cellular immune responses against p24
in mice (43), and tumor-derived HSP70 is taken up by immature DCs and
causes production of TH1 cytokines such as IFN- This report demonstrates for the first time that HSP70-induced
proinflammatory cytokine production is mediated via the MyD88/NF- We thank Rajani Mallick and Rahilya Napoli
for expert technical assistance, The Kraft Family Blood Center,
Dana-Farber Cancer Institute for the freshly drawn peripheral venous
blood, Dr. Jay Harris for departmental support, and Yasuhiro Yoshida
and Yoshinobu Koyama for preparation of the MyD88DN and TLR4DN and the
stable HEK293 IL-1RI expressing cell lines.
*
This work was supported by National Institutes of Health
Grants CA47407, CA31303, CA50642, and CA77465 (to S. K. C.),
a Joint Center for Radiation Therapy Foundation Grant (to A. A.),
National Institutes of Health Grants CA68544 and AI44122 (to
P. E. A.) and the Deutsche Forschungsgemeinschaft (to M. R.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
**
To whom correspondence may be addressed: Dept. of Radiation
Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney St. (D810), Boston, MA 02115. Tel.: 617-632-3885; Fax: 617-632-4599; E-mail: stuart_calderwood@dfci.harvard.edu.
Published, JBC Papers in Press, February 8, 2002, DOI 10.1074/jbc.M200497200
The abbreviations used are:
TLR, Toll-like receptor;
IRAK, IL-1R-associated kinase;
LPS, lipopolysaccharide;
HSP, heat shock protein;
IL, interleukin;
DN, dominant negative;
TNF-
Novel Signal Transduction Pathway Utilized by Extracellular
HSP70
ROLE OF Toll-LIKE RECEPTOR (TLR) 2 AND TLR4*
,
,
,
, and
**
Department of Radiation Oncology,
Dana-Farber Cancer Institute, Harvard Medical School, Boston,
Massachusetts 02115, the § Department of Hematology and
Oncology, University of Regensburg Medical Hospital, Regensburg 93042, Germany, the ¶ Department of Medicine, Harvard Medical School and
New England Baptist Bone and Joint Institute, Beth Israel Deaconess
Medical Center, Boston, Massachusetts 02115, and the
Department
of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard
Medical School, Boston, Massachusetts 02115
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
B, and up-regulate the expression of pro-inflammatory cytokines in human monocytes. Here for the first time, we report that
HSP70-induced proinflammatory cytokine production is mediated via the
MyD88/IRAK/NF-
B signal transduction pathway and that HSP70 utilizes
both TLR2 (receptor for Gram-positive bacteria) and TLR4 (receptor for
Gram-negative bacteria) to transduce its proinflammatory signal in a
CD14-dependent fashion. These studies now pave the way for
the development of highly effective pharmacological or molecular tools
that will either up-regulate or suppress HSP70-induced functions in
conditions where HSP70 effects are desirable (cancer) or disorders
where HSP70 effects are undesirable (arthritis and arteriosclerosis).
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
2-integrins (CD11/CD18), complement receptors
(CR1/CD35), and C-type lectins are expressed either as soluble proteins
or plasma membrane-bound proteins that recognize invariant
molecular structures called pathogen-associated molecular patterns
(e.g. LPS, peptidoglycan, unmethylated CpG DNA, bacterial
lipoprotein, and mannans of yeast), that are shared by numerous
pathogens but are not normally expressed on host tissues (2). Recent
studies on the recognition of microbial pathogen-associated molecular patterns have highlighted the central role played by one group of
pattern recognition receptors, the TLR, in pathogen
recognition and host defense (see review in Refs. 4-6). TLRs are
similar in sequence and structure to the Drosophila Toll
protein and they share a conserved extracellular leucine-rich region
important for ligand binding. Both Toll and TLRs are type 1 transmembrane proteins whose intracellular signaling domains have a
Toll/IL-lR homology motif (7-9). Toll was originally identified as an
essential component of dorsal-ventral development in flies, and has
since been linked to an immune response against fungal infection in adult flies (10, 11). The mammalian homologues of Toll also control
innate immune responses through conserved signaling pathways. An
adapter protein, MyD88, binds to a receptor Toll/IL-lR-domain through
its own Toll/IL-lR motif, while a death domain on its C terminus
recruits IL-1R-associated kinase (IRAK) to the complex. IRAK is then
autophosphorylated, and released from the complex to bind TRAF6, which
can then activate either the NF-
B pathway or the mitogen-activated
protein kinase cascade (8). The TLR family is a fast growing family
whose ligands have not all been identified. The most well characterized
TLRs are TLR2 and TLR4. TLR4 initiates signaling cascades in response
to lipopolysaccharide (LPS), the abundant glycolipid of the outer
membrane of Gram-negative bacteria, Taxol, or HSP60, while TLR2
initiates the signal cascade in response to Gram-positive bacteria,
Mycoplasma, Yeast, and Spirochetes.
B promoter
activity is MyD88-dependEnt, CD14-dependEnt, and is transduced via both
TLR2 and TLR4. In addition, we show that TLR2 and TLR4 synergize to
greatly augment HSP70-induced cytokine production. The physiological
relevance of extracellular HSP70s ability to synergistically activate
proinflammatory cytokine production helps elucidate recent findings
indicating that HSP70 is a potent adjuvant for eliciting immune
responses and a powerful inducer of anti-tumor immunity.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
B reporter luciferase plasmid and,
to correct for differences in transfection efficiency, each group of
cells was transfected with 90 ng of pSV40/LACZ and
co-transfected with either 1 µg of CD14 or 1 µg of TLR2DN or 1 µg
of TLR4DN or 3 µg of MyD88DN or 3 µg of empty vector and incubated
overnight. The ratio of luciferase activity to
-galactosidase
activity in each sample served as a measure of normalized luciferase
activity. Following the various treatment protocols, cell extracts were
prepared for determination of luciferase activity using enhanced
luciferase assay reagents (Analytical Luminescence) according to the
manufacturer's instructions. Luciferase assays were performed on a
Monolight 2010 luminometer (Analytical Luminescence) for 20 s and
results are expressed as the ratio of luciferase to
-galactosidase
and are the mean ± S.D. of experiments performed in triplicate
and repeated at least three times.
-PE or
anti-human MHCII (1 µl/106 cells; BD PharMingen, Mountain
View, CA) for 40 min at room temperature in the dark. Cells were then
washed twice in phosphate-buffered saline and analyzed by flow
cytometry. Flow cytometric analysis was performed on a FACScan with
Lysis II software program (BD PharMingen). Individual cells were
gated on the basis of forward (FSC) and orthogonal scatter (SSC). The
photomultiplier for fluorescein isothiocyanate
(FL1-height) or PE (FL2-height) was set on a logarithmic scale.
Cell debris was excluded by raising the FSC-height PMT threshold. The
flow rate was adjusted to <200 cells/s and at least 10,000 cells were
analyzed for each sample.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
B Promoter Activity--
We (15,
18) and others (16, 19) have recently shown that extracellular
recombinant HSP70 (StressGen Biotechnologies; Victoria, BC, Canada)
activates proinflammatory cytokine production by antigen presenting
cells. Among the proinflammatory cytokines induced by HSP70 interaction
with human monocytes, we identified IL-1
, IL-6, and TNF-
(15,
18). IL-1
has been shown to be produced following interaction at the
surface membrane by complex formation between extracellular IL-1 and
the transmembrane IL-1R type I (IL-1R1) and IL-1R accessory proteins
(IL-1RAcP) (reviewed in Ref. 20). The resulting intracellular signaling
cascade recruits two IRAK, IRAK1 and IRAK2, and an adapter protein
MyD88 (21). Interestingly, IL-1 receptors (22, 23), IL-18 receptor
(24-26), and TLRs (3, 27), signal through the MyD88/IRAK-NF-
B
signal transduction pathway. To test whether recombinant HSP70-induced signaling cascade occurs via a similar pathway, THP1 monocytic cells
were treated with various concentrations of HSP70 and NF-
B promoter
activity was measured using a
B-luciferase reporter construct after
2 h incubation at 37 °C (Fig. 1).
HSP70 dose dependently increased NF-
B promoter activity in THP1
monocytic cells (Fig. 1). Control protein OVA used at equimolar
concentrations did not up-regulate NF-
B promoter activity
significantly above background levels (Fig. 1). HSP70 at a
concentration of 0.1 µg/ml resulted in submaximal activation of
NF-
B promoter activity, and unless otherwise stated, was the
concentration we used in subsequent experiments. Luciferase activity
was observed at Hsp70 concentrations as low as 0.01 µg/ml (0.14 nM).

View larger version (13K):
[in a new window]
Fig. 1.
Dose response curve for extracellular
HSP70-induced NF-
B activity. THP1
monocytic cells were stimulated with various concentrations of HSP70
(filled circles) or protein control, OVA (open
circles), and incubated for 2 h at 37 °C after which
extracts were prepared for determination of luciferase activity as
described under "Experimental Procedures." Results are expressed as
the ratio of luciferase (luc) to
-galactosidase
(
-gal) and are the mean ± S.D. of four experiments
performed in triplicate. *, p < 0.05 versus
protein control, OVA (Student's t test).
B Promoter Activity: Role
of CD14 and MyD88--
To determine the mechanism by which HSP70
activates the signal cascade that results in the activation of NF-
B
promoter activity, we used HEK293 cells. HEK293 cells do not express
IL-1R, CD14, or TLR. For these studies, we generated HEK293 cells that
stably express IL-1R (293-IL-1R), TLR2 (293-TLR2), and TLR4 (293-TLR4). LPS (0.1 µg/ml) but not Hsp70 (0.1 µg/ml) activated NF-
B
promoter activity in 293-TLR4 cells (Fig.
2). However, HSP70-induced NF-
B promoter activity was strongly restored in 293-TLR4 cells transiently transfected with CD14 to a level comparable with LPS-induced NF-
B promoter activation (Fig. 2). This is in line with our previous findings in which we demonstrated that HSP70 stimulates proinflammatory cytokine production in a CD14-dependant fashion (15). Transient transfection of 293-TLR4 cells with CD14 and the dominant negative MyD88 (MyD88DN) completely abrogated HSP70-induced and LPS-induced NF-
B promoter activity (Fig. 2). To rule out bacterial contamination of HSP70, we preincubated 293-TLR4 cells with Polymyxin B, a potent LPS
inhibitor (28, 29). Preincubation of 293-TLR4 cells with Polymyxin B
(10 µM) 30-60 min before activation abrogated
LPS-induced but not HSP70-induced NF-
B promoter activity (Fig. 2).
As an additional control, boiling HSP70 at 100 °C for 1 h
completely abrogated HSP70-induced, but not LPS-induced NF-
B
promoter activity (data not shown). Furthermore, HSP70 but not LPS
induced a rapid intracellular Ca2+ flux in monocytes (15)
(data not shown). Taken together, these results demonstrate that
HSP70-induced NF-
B activity is dependant on CD14 to signal through
TLR4, which initiates a signal cascade that is transduced via MyD88
(Fig. 2). As an additional control to demonstrate that HSP70-induced
signaling specifically occurs through TLR4 and CD14, we used HEK293
cells stably transfected with IL-1R (293-IL-1R). We hypothesized that
if the HSP70 signaling cascade is specific, HSP70 will not activate
NF-
B promoter activity in 293-IL-1R. This is because, although both
IL-1
and TLR transduce signals via the Toll/IL-lR domain in a
MyD88/IRAK/TRAF6-NF-
B signaling pathway, the external surface
receptors for IL-1R and TLR are different. As expected, IL-1
but not
HSP70 activated NF-
B promoter activity in 293-IL-1R cells (Fig.
3). For additional specificity,
IL-1
-induced NF-
B promoter activity was abrogated in 293-IL1R
cells transiently transfected with MyD88DN (Fig. 3). Taken together
these results show that the external receptor for HSP70 is not the
IL-1R and that extracellular HSP70 cannot directly interact with
molecules downstream of TLR or IL-1R.

View larger version (14K):
[in a new window]
Fig. 2.
CD14 and TLR are required for optimum
activation of NF-
B by extracellular
HSP70. HEK293-TLR4 cells were transfected with 1 µg of NF-
B
reporter luciferase plasmid alone or co-transfected with 3 µg of
MyD88DN or CD14 or empty vector. Cells were preincubated with or
without Polymyxin B (10 mM) then stimulated with 0.1 µg/ml HSP70 (filled bars) or 0.1 µg/ml LPS (gray
bars) or 0.1 µg/ml OVA (open bars) and incubated for
2 h after which extracts were prepared for determination of
luciferase activity. Bars represent the ratio of luciferase
(luc) to
-galactosidase (
-gal) and are the
mean ± S.D. of three experiments performed in triplicate. *,
p < 0.05 versus protein control, OVA
(Student's t test).

View larger version (11K):
[in a new window]
Fig. 3.
Extracellular HSP70 does not signal through
IL-1R. HEK293 wild type (open bars) or HEK293-IL-1R
cells (filled bars) were transfected with 1 µg of IL-1
reporter luciferase plasmid alone or co-transfected with 3 µg of
MyD88DN or CD14 or empty vector. Cells were stimulated with 0.1 µg/ml
HSP70 or IL-1
and incubated for 2 h after which extracts were
prepared for determination of luciferase activity. Bars
represent the ratio of luciferase (luc) to
-galactosidase
(
-gal) and are the mean ± S.D. of two experiments
performed in triplicate. *, p < 0.05 versus
respective controls (Student's t test).
B Activation: Role
of TLRs--
We also examined a possible role of TLR2 in extracellular
HSP70-mediated signaling. To our surprise, stimulation of 293-TLR2 cells co-transfected with CD14 with HSP70 (0.1 µg/ml) induced potent
NF-
B promoter activity to a level equivalent to 293-TLR4 cells
co-transfected with CD14 (Fig. 4). To
confirm that HSP70 was indeed signaling through TLR2 and CD14, we
pretreated 293-TLR2 cells with anti-TLR2 before stimulation with HSP70.
Pretreatment of 293-TLR2 cells with anti-TLR2 completely abrogated
HSP70-induced NF-
B promoter activity in HEK293-TLR2, but not
HEK293-TLR4 cells (Fig. 4). We then asked the question as to what kind
of signaling would occur if both TLR2 and TLR4 were expressed on the
surface of HEK293 cells. Therefore, HEK293 cells were generated that
stably expressed both TLR2 and TLR4 (293-TLR2+4). Treatment of
293-TLR2+4 with HSP70 resulted in the synergistic activation of NF-
B
promoter activity in a CD14-dependant fashion (Fig.
5). The HSP70-induced NF-
B promoter
activity was only partially inhibited by co-transfection of 293-TLR2+4
with dominant negative TLR2 (TLR2DN) or dominant negative TLR4 (TLR4DN)
(Fig. 5). Co-transfection of 293-TLR2+4 with both TLR2DN and TLR4DN
completely abrogated HSP70-induced CD14-dependent NF-
B
promoter activity (Fig. 5). On the other hand, co-transfection of
293-TLR2+4 with CD14 plus MyD88DN only partially inhibited
HSP70-induced NF-
B promoter activity (Fig. 6). It has recently been suggested that
although TLR4 might act as a homodimer, TLR2 cannot form functional
homodimers and acts only in combination with selected TLR proteins,
forming heterodimers with, for example, TLR1 and TLR6 (30). Taken
together, these results suggest that a combination of TLR2 and TLR4
plus CD14 triggers HSP70-induced MyD88-independent signaling and
implies that TRL2 can form functional homodimers as well as functional heterodimers with TLR4 for HSP70-induced signaling.

View larger version (13K):
[in a new window]
Fig. 4.
HSP70-induced signal cascade utilizes both
TLR2 and TLR4 to activate NF-
B activity.
HEK293 wild type cells (open bars) or HEK293-TLR2 cells
(gray bars) or HEK293-TLR4 cells (filled bars)
were transfected with 1 µg of NF-
B reporter luciferase plasmid
alone or co-transfected with 3 µg of CD14 or empty vector. Cells
pretreated with anti-TLR2 for 30 min before stimulation with 0.1 µg/ml HSP70 or 0.1 µg/ml OVA and incubated for 2 h after which
extracts were prepared for determination of luciferase activity.
Bars represent the ratio of luciferase (luc) to
-galactosidase (
-gal) and are the mean ± S.D. of
three experiments performed in triplicate. *, p < 0.05 versus respective controls (Student's t
test).

View larger version (17K):
[in a new window]
Fig. 5.
Exogenous HSP70 synergistically augments
NF-
B promoter activity in HEK293 cells
expressing both TLR2 and TLR4. HEK293 wild type (open
bars), HEK293-TLR2 cells (left hatched bars),
HEK293-TLR4 cells (right hatched bars), or HEK293-TLR2+4
cells (filled bars) were transfected with 1 µg of NF-
B
reporter luciferase plasmid alone or co-transfected with 3 µg of CD14
or TLR2DN or TLR4DN or TLR2DN + TLR4DN or empty vector. Cells were
stimulated with 0.1 µg/ml HSP70 or 0.1 µg/ml OVA and incubated for
2 h after which extracts were prepared for determination of
luciferase activity. Bars represent the ratio of luciferase
(luc) to
-galactosidase (
-gal) and are the
mean ± S.D. of four experiments performed in triplicate. *,
p < 0.05 versus respective controls
(Student's t test).

View larger version (14K):
[in a new window]
Fig. 6.
Synergistic activation of
NF-
B promoter by co-expression of both TLR2
and TLR4 on HEK293 cells is MyD88-independent. HEK293-TLR2 cells
(open bars), HEK293-TLR4 cells (gray bars), or
HEK293-TLR2+4 cells (filled bars) were transfected with 1 µg of NF-
B reporter luciferase plasmid alone or co-transfected
with 3 µg of CD14 or MyD88DN or TLR2DN + TLR4DN or empty vector.
Cells were stimulated with 0.1 µg/ml HSP70 or OVA and incubated for
2 h after which extracts were prepared for determination of
luciferase activity. Bars represent the ratio of luciferase
(luc) to
-galactosidase (
-gal) and are the
mean ± S.D. of three experiments performed in triplicate. *,
p < 0.05 versus respective controls
(Student's t test).
B Activity: Linking
Innate and Adaptive Immunity--
The functional consequence of the
interaction between extracellular HSP70 and human monocytes has
recently been investigated. We (15, 18) and others (16) have recently
demonstrated that extracellular HSP70 induces potent cytokine
production in human monocytes via interaction with CD14. These findings
suggest that HSPs may not only serve as a vehicle for antigenic
peptides but also as a "danger signal" to the innate and specific
immune system as suggested for other endogenous activators of antigen
presenting cells (31). Once activated, mature antigen presenting
cells display their full co-stimulatory potential and are able
to communicate very effectively with naive T-helper lymphocytes and
prime cytotoxic T lymphocytes to mount potent and effective adaptive
immune responses. Therefore, we investigated whether HSP70 was able to
deliver a maturation signal to DCs. Human DCs were generated in
vitro from peripheral blood mononuclear cells obtained from
freshly drawn peripheral venous blood and incubated with granulocyte
macrophage-colony stimulating factor as previously described (32).
Treatment of human DCs with HSP70 and LPS augmented pro-inflammatory
cytokine, IL-1
, IL-12, and TNF-
production, as determined by
enzyme-linked immunosorbent assay (Table
I). To exclude the possibility that this
effect was due to contamination of the protein preparation by
endotoxins such as LPS, boiling (100 °C, 1 h) HSP70 abrogated cytokine production, whereas LPS-induced cytokine production was not
significantly abrogated by boiling (Table I). The ability of antigen
presenting cells to induce an immune response depends both on
the regulated expression of cytokines, which act directly on T
lymphocytes and on the up-regulation of co-stimulatory molecules on DCs
(32, 33). In line with these findings, intact HSP70 and LPS, but not
boiled HSP70, up-regulated the expression of co-stimulatory molecules
CD86 (B7.2) and myosin heavy chain class II on human DCs, as determined
by flow cytometric analysis (Table I). Treatment of irradiated immature
DCs with HSP70 resulted in augmentation in proliferation of T
lymphocytes 7-8-fold greater than in T lymphocytes incubated with
irradiated immature DCs treated with either boiled HSP70 or control
protein OVA, as determined after 5 days by incorporation of
[3H]TdR (data not shown). Proliferation of mature DCs was
significantly lower as compared with immature DCs in response to
stimulation with intact HSP70 and LPS or boiled LPS (Table I). This is
in agreement with previous data showing that activated mature DCs grow
slower than non-activated immature DCs (Table I). Treatment of DCs with
boiled HSP70 did not result in significant proliferation above control
levels (Table I). The ability of HSP70 to induce cytokine and
co-stimulatory molecule expression on DCs suggests that it might play
an important role in linking innate and adaptive immune responses.
Chaperokine effect of extracellular HSP70: induction of cytokine
production, co-stimulatory molecule expression and proliferation of DCs

View larger version (35K):
[in a new window]
Fig. 7.
CD14, TLR2, and TLR4 are required for potent
HSP70-induced IL-6 production. HEK293 cells were grown on
Falcon culture slides (BD Labware, Franklin Lakes, NJ) overnight and
then co-transfected for 24 h with vector alone or CD14 or CD14 + TLR2 or CD14 + TLR2 + TLR4. Cells were then stimulated with 100 ng/ml
HSP70 (right panels) or control (100 ng/ml OVA; left
panels) at 37 °C for 4 h in the presence of 10 mM brefeldin A (Sigma). After this cells were
simultaneously fixed and permeabilized using the
Cytofix/CytopermTM kit (BD Biosciences, San Diego, CA)
according to the manufacturer's instructions and counterstained with
anti-human IL-6-fluorescein isothiocyanate (BD Biosciences). One drop
of mounting media containing 4,6-diamidino-2-phenylindole stain to
visualize nuclear staining (Oncogene, Boston, MA) was placed onto the
glass slide before the coverslip was sealed with nail polish. Results
are a representative of four independently performed with similar
results. Results show (A) fluorescence image showing nuclear
morphology (blue) and intracellular IL-6 production
(green), and (B) phase-contrast image of all
cells on the culture slide. Results are a representative of two
independently performed experiments with similar results.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
B signal transduction pathway and that HSP70 utilizes both TLR2 (receptor
for Gram-positive bacteria) and TLR4 (receptor for Gram-negative bacteria) to transduce its proinflammatory signal in a
CD14-dependent fashion. The biological significance of
these findings now pave the way for the development of highly effective
pharmacological or molecular tools that will either up-regulate or
suppress HSP70-induced functions in conditions where HSP70 effects are
desirable or disorders where HSP70 effects are undesirable.
production in response to
yeast and Gram-positive bacterial products, but not Gram-negative
bacteria. These findings suggest that TLR proteins might act as dimers
and in some cases as heterodimers. Indeed, it was suggested that TLR4
might behave as a homodimer, whereas TLR2 cannot form functional
homodimers and acts only in combination with selected TLR proteins,
like TLR1 and TLR6 (for review, see Refs. 30). In this report, we show
that HSP70 can interact with both TLR2 and TLR4 in a
CD14-dependent fashion, and that this combination is
particularly effective resulting in the synergistic activation of
NF-
B activity (Figs. 5 and 6). The significance of these findings
suggest how a restricted family of receptors, like the TLR family, is
able to discriminate between the wide spectrum of TLR stimuli that is
known to exist. Extensive insight into the complex nature in which DCs
discriminate different pathogens (Escherichia coli,
Candida albicans, and influenza virus) at a genetic
level has recently been initiated using a novel DNA microarray method
that reveals the genome-wide location of DNA-bound proteins (38, 39).
In another report, it was recently shown that LPS activates cytokine
production via a MyD88-dependent pathway and activates
co-stimulatory molecule expression via a MyD88-independent pathway
(40). Experiments showing that HSP70-induced NF-
B promoter activity
is only partially inhibited by MyD88DN in HEK293 cells co-expressing
both TLR2 and TLR4 (Fig. 6), suggest that under certain conditions
HSP70 might signal by both a MyD88-dependent and
MyD88-independent signal transduction pathway. To conclusively answer
this question experiments are now underway to test HSP70-induced cytokine and co-stimulatory molecule expression in primary cultures of
human DC after transient transfection with MyD88DN, TLR2DN, and/or
TLR4DN. At the submission of this report, a novel adaptor protein was
described known as MyD88-adaptor-like and shown to be an adaptor for
TLR4 signaling (41). In addition, MyD88-adaptor-like was demonstrated
to abrogate TLR4, but not IL-1 or IL-18-induced signaling (41). If
confirmed, studies into the role of MyD88-adaptor-like in HSP70-induced
signaling could provide useful information on how extracellular HSP70
mediates its proinflammatory and anti-tumor effects.
, TNF-
, and IL-12
(44). In this report, we demonstrate that the effects observed in
vitro are applicable to the biological system. Thus, experiments
with HEK293 cells confirmed that TLR2 and TLR4 work synergistically to
potently augment intracellular IL-6 production in response to HSP70
stimulation (Fig. 7A). This demonstrates the specificity of
the HSP70-induced signaling pathway and its dependence on TLR and the
MyD88/NF-
B signal transduction pathway.
B signal transduction pathway and that HSP70 utilizes both TLR2 (receptor
for Gram-positive bacteria) and TLR4 (receptor for Gram-negative bacteria) to transduce its proinflammatory signal in a
CD14-dependent fashion. These findings now pave the way for
the development of highly effective pharmacological or molecular tools
that will either up-regulate or suppress HSP70-induced functions in
conditions where HSP70 effects are desirable or disorders where HSP70
effects are undesirable.
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES
![]()
ABBREVIATIONS
, tumor necrosis factor-
;
[3H]TdR, [3H]methylthymidine;
OVA, ovalbumin;
DC, dendritic cell.
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Fearon, D. T.,
and Locksley, R. M.
(1996)
Science
272,
50-53[Abstract] 2.
Medzhitov, R.,
and Janeway, C. A. J.
(1997)
Curr. Opin. Immunol.
9,
4-9[CrossRef][Medline]
[Order article via Infotrieve] 3.
Medzhitov, R.,
Preston-Hurlburt, P.,
and Janeway, C. A., Jr.
(1997)
Nature
388,
394-397[CrossRef][Medline]
[Order article via Infotrieve] 4.
Anderson, K. V.
(2000)
Curr. Opin. Immunol.
12,
13-19[CrossRef][Medline]
[Order article via Infotrieve] 5.
Janeway, C. A. J.
(1999)
Curr. Biol.
9,
R879-R882[CrossRef][Medline]
[Order article via Infotrieve] 6.
Zhang, G.,
and Ghosh, S.
(2001)
J. Clin. Invest.
107,
13-19[Medline]
[Order article via Infotrieve] 7.
Aderem, A.,
and Ulevitch, R. J.
(2000)
Nature
406,
782-787[CrossRef][Medline]
[Order article via Infotrieve] 8.
Kopp, E. B.,
and Medzhitov, R.
(1999)
Curr. Opin. Immunol.
11,
13-18[CrossRef][Medline]
[Order article via Infotrieve] 9.
Rock, F. L.,
Hardiman, G.,
Timans, J. C.,
Kastelein, R. A.,
and Bazan, J. F.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
588-593 10.
Lemaitre, B.,
Nicolas, E.,
Michaut, L.,
Reichhart, J. M.,
and Hoffmann, J. A.
(1996)
Cell
86,
973-983[CrossRef][Medline]
[Order article via Infotrieve] 11.
Muzio, M.,
and Mantovani, A.
(2000)
Microbes Infect.
2,
251-255[CrossRef][Medline]
[Order article via Infotrieve] 12.
Craig, E. A.,
and Gross, C. A.
(1991)
Trends Biochem. Sci.
16,
135-140[CrossRef][Medline]
[Order article via Infotrieve] 13.
Lindquist, S.,
and Craig, E. A.
(1988)
Annu. Rev. Genet.
22,
631-677[CrossRef][Medline]
[Order article via Infotrieve] 14.
Ohashi, K.,
Burkart, V.,
Flohe, S.,
and Kolb, H.
(2000)
J. Immunol.
164,
558-561 15.
Asea, A.,
Kraeft, S. K.,
Kurt-Jones, E. A.,
Stevenson, M. A.,
Chen, L. B.,
Finberg, R. W.,
Koo, G. C.,
and Calderwood, S. K.
(2000)
Nat. Med.
6,
435-442[CrossRef][Medline]
[Order article via Infotrieve] 16.
Moroi, Y.,
Mayhew, M.,
Trcka, J.,
Hoe, M. H.,
Takechi, Y.,
Hartl, F. U.,
Rothman, J. E.,
and Houghton, A. N.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
3485-3490 17.
Asea, A.
(1995)
The Role of Histamine in the Regulation of Natural Killer Cells Doctoral dissertation
, University of Göteborg, Göteborg, Sweden, 1-88
18.
Asea, A.,
Kabingu, E.,
Stevenson, M. A.,
and Calderwood, S. K.
(2000)
Cell Stress Chaperones
5,
425-431[CrossRef][Medline]
[Order article via Infotrieve] 19.
Binder, R. J.,
Harris, M. L.,
Menoret, A.,
and Srivastava, P. K.
(2000)
J. Immunol.
165,
2582-2587 20.
Auron, P. E.
(1998)
Cytokine Growth Factor Rev.
9,
221-237[CrossRef][Medline]
[Order article via Infotrieve] 21.
Jensen, L. E.,
Muzio, M.,
Mantovani, A.,
and Whitehead, A. S.
(2000)
J. Immunol.
164,
5277-5286 22.
Wesche, H.,
Henzel, W. J.,
Shillinglaw, W., Li, S.,
and Cao, Z.
(1997)
Immunity
7,
837-847[CrossRef][Medline]
[Order article via Infotrieve] 23.
Muzio, M., Ni, J.,
Feng, P.,
and Dixit, V. M.
(1997)
Science
278,
1612-1615 24.
Kanakaraj, P.,
Ngo, K., Wu, Y.,
Angulo, A.,
Ghazal, P.,
Harris, C. A.,
Siekierka, J. J.,
Peterson, P. A.,
and Fung-Leung, W. P.
(1999)
J. Exp. Med.
189,
1129-1138 25.
Adachi, O.,
Kawai, T.,
Takeda, K.,
Matsumoto, M.,
Tsutsui, H.,
Sakagami, M.,
Nakanishi, K.,
and Akira, S.
(1998)
Immunity
9,
143-150[CrossRef][Medline]
[Order article via Infotrieve] 26.
Thomassen, E.,
Bird, T. A.,
Renshaw, B. R.,
Kennedy, M. K.,
and Sims, J. E.
(1998)
J. Interferon Cytokine Res.
18,
1077-1088[Medline]
[Order article via Infotrieve] 27.
Medzhitov, R.,
Preston-Hurlburt, P.,
Kopp, E.,
Stadlen, A.,
Chen, C.,
Ghosh, S.,
and Janeway, C. A., Jr.
(1998)
Mol. Cell
2,
253-258[CrossRef][Medline]
[Order article via Infotrieve] 28.
Golenbock, D. T.,
Hampton, R. Y.,
Qureshi, N.,
Takayama, K.,
and Raetz, C. R.
(1991)
J. Biol. Chem.
266,
19490-19498 29.
Duff, G. W.,
and Atkins, E.
(1982)
J. Immunol. Methods
52,
333-340[CrossRef][Medline]
[Order article via Infotrieve] 30.
Heldwein, K. A.,
Goldenbock, D. T.,
and Fenton, M. J.
(2001)
Mod. Asp. Immunobiol.
1,
249-252
31.
Matzinger, P.
(1998)
Semin. Immunol.
10,
399-415[CrossRef][Medline]
[Order article via Infotrieve] 32.
Inaba, K.,
Witmer-Pack, M.,
Inaba, M.,
Hathcock, K. S.,
Sakuta, H.,
Azuma, M.,
Yagita, H.,
Okumura, K.,
Linsley, P. S.,
Ikehara, S.,
Muramatsu, S.,
Hodes, R. J.,
and Steinman, R. M.
(1994)
J. Exp. Med.
180,
1849-1860 33.
Hathcock, K. S.,
Laszlo, G.,
Pucillo, C.,
Linsley, P.,
and Hodes, R. J.
(1994)
J. Exp. Med.
180,
631-640 34.
Fenton, M. J.,
and Goldenbock, D. T.
(1998)
J. Leukocyte Biol.
64,
25-32[Abstract] 35.
Ulevitch, R. J.,
and Tobias, P. S.
(1995)
Annu. Rev. Immunol.
13,
437-457[CrossRef][Medline]
[Order article via Infotrieve] 36.
Ulevitch, R. J.,
and Tobias, P. S.
(1994)
Curr. Opin. Immunol.
6,
125-130[CrossRef][Medline]
[Order article via Infotrieve] 37.
Ozinsky, A.,
Underhill, D. M.,
Fontenot, J. D.,
Hajjar, A. M.,
Smith, K. D.,
Wilson, C. B.,
Schroeder, L.,
and Aderem, A.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
13766-13771 38.
Huang, Q.,
Liu do, N.,
Majewski, P.,
Schulte le, A. C.,
Korn, J. M.,
Young, R. A.,
Lander, E. S.,
and Hacohen, N.
(2001)
Science
294,
870-875 39.
Ren, B.,
Robert, F.,
Wyrick, J. J.,
Aparicio, O.,
Jennings, E. G.,
Simon, I.,
Zeitlinger, J.,
Schreiber, J.,
Hannett, N.,
Kanin, E.,
Volkert, T. L.,
Wilson, C. J.,
Bell, S. P.,
and Young, R. A.
(2000)
Science
290,
2306-2309 40.
Kaisho, T.,
and Akira, S.
(2001)
Trends Immunol.
22,
78-83[CrossRef][Medline]
[Order article via Infotrieve] 41.
Fitzgerald, K. A.,
Palsson-McDermott, E. M.,
Bowie, A. G.,
Jefferies, C. A.,
Mansell, A. S.,
Brady, G.,
Brint, E.,
Dunne, A.,
Gray, P.,
Harte, M. T.,
McMurray, D.,
Smith, D. E.,
Sims, J. E.,
Bird, T. A.,
and O'Neill, L. A.
(2001)
Nature
413,
78-83[CrossRef][Medline]
[Order article via Infotrieve] 42.
Moseley, P.
(2000)
Immunopharmacology
48,
299-302[CrossRef][Medline]
[Order article via Infotrieve] 43.
Suzue, K.,
and Young, R. A.
(1996)
J. Immunol.
156,
873-879[Abstract] 44.
Todryk, S.,
Melcher, A. A.,
Hardwick, N.,
Linardakis, E.,
Bateman, A.,
Colombo, M. P.,
Stoppacciaro, A.,
and Vile, R. G.
(1999)
J. Immunol.
163,
1398-1408
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
K. N. Khan, M. Kitajima, T. Imamura, K. Hiraki, A. Fujishita, I. Sekine, T. Ishimaru, and H. Masuzaki Toll-like receptor 4-mediated growth of endometriosis by human heat-shock protein 70 Hum. Reprod., October 1, 2008; 23(10): 2210 - 2219. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Galloway, T. Shin, N. Huber, T. Eismann, S. Kuboki, R. Schuster, J. Blanchard, H. R. Wong, and A. B. Lentsch Activation of hepatocytes by extracellular heat shock protein 72 Am J Physiol Cell Physiol, August 1, 2008; 295(2): C514 - C520. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Rayner, Y.-X. Chen, M. McNulty, T. Simard, X. Zhao, D. J. Wells, J. de Belleroche, and E. R. O'Brien Extracellular Release of the Atheroprotective Heat Shock Protein 27 Is Mediated by Estrogen and Competitively Inhibits acLDL Binding to Scavenger Receptor-A Circ. Res., July 18, 2008; 103(2): 133 - 141. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Valentinis, A. Capobianco, F. Esposito, A. Bianchi, P. Rovere-Querini, A. A. Manfredi, and C. Traversari Human recombinant heat shock protein 70 affects the maturation pathways of dendritic cells in vitro and has an in vivo adjuvant activity J. Leukoc. Biol., July 1, 2008; 84(1): 199 - 206. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Zou, L. Ao, J. C. Cleveland Jr., X. Yang, X. Su, G.-Y. Cai, A. Banerjee, D. A. Fullerton, and X. Meng Critical role of extracellular heat shock cognate protein 70 in the myocardial inflammatory response and cardiac dysfunction after global ischemia-reperfusion Am J Physiol Heart Circ Physiol, June 1, 2008; 294(6): H2805 - H2813. [Abstract] [Full Text] [PDF] |
||||